IBDEI1H3 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,23556,0)
 ;;=A69.22^^105^1174^96
 ;;^UTILITY(U,$J,358.3,23556,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23556,1,3,0)
 ;;=3^Neurologic Disorders d/t Lyme Disease
 ;;^UTILITY(U,$J,358.3,23556,1,4,0)
 ;;=4^A69.22
 ;;^UTILITY(U,$J,358.3,23556,2)
 ;;=^5000377
 ;;^UTILITY(U,$J,358.3,23557,0)
 ;;=A52.10^^105^1174^97
 ;;^UTILITY(U,$J,358.3,23557,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23557,1,3,0)
 ;;=3^Neurosyphilis Symptomatic,Unspec
 ;;^UTILITY(U,$J,358.3,23557,1,4,0)
 ;;=4^A52.10
 ;;^UTILITY(U,$J,358.3,23557,2)
 ;;=^5000291
 ;;^UTILITY(U,$J,358.3,23558,0)
 ;;=A52.3^^105^1174^98
 ;;^UTILITY(U,$J,358.3,23558,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23558,1,3,0)
 ;;=3^Neurosyphilis,Unspec
 ;;^UTILITY(U,$J,358.3,23558,1,4,0)
 ;;=4^A52.3
 ;;^UTILITY(U,$J,358.3,23558,2)
 ;;=^5000298
 ;;^UTILITY(U,$J,358.3,23559,0)
 ;;=N70.92^^105^1174^99
 ;;^UTILITY(U,$J,358.3,23559,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23559,1,3,0)
 ;;=3^Oophoritis,Unspec
 ;;^UTILITY(U,$J,358.3,23559,1,4,0)
 ;;=4^N70.92
 ;;^UTILITY(U,$J,358.3,23559,2)
 ;;=^5015807
 ;;^UTILITY(U,$J,358.3,23560,0)
 ;;=M86.40^^105^1174^100
 ;;^UTILITY(U,$J,358.3,23560,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23560,1,3,0)
 ;;=3^Osteomyelitis w/ Draining Sinus,Chronic,Unspec Site
 ;;^UTILITY(U,$J,358.3,23560,1,4,0)
 ;;=4^M86.40
 ;;^UTILITY(U,$J,358.3,23560,2)
 ;;=^5014583
 ;;^UTILITY(U,$J,358.3,23561,0)
 ;;=M86.00^^105^1174^103
 ;;^UTILITY(U,$J,358.3,23561,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23561,1,3,0)
 ;;=3^Osteomyelitis,Acute Hematogenous,Unspec Site
 ;;^UTILITY(U,$J,358.3,23561,1,4,0)
 ;;=4^M86.00
 ;;^UTILITY(U,$J,358.3,23561,2)
 ;;=^5014497
 ;;^UTILITY(U,$J,358.3,23562,0)
 ;;=M86.50^^105^1174^104
 ;;^UTILITY(U,$J,358.3,23562,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23562,1,3,0)
 ;;=3^Osteomyelitis,Chronic Hematogenous,Unspec Site
 ;;^UTILITY(U,$J,358.3,23562,1,4,0)
 ;;=4^M86.50
 ;;^UTILITY(U,$J,358.3,23562,2)
 ;;=^5014607
 ;;^UTILITY(U,$J,358.3,23563,0)
 ;;=M86.30^^105^1174^105
 ;;^UTILITY(U,$J,358.3,23563,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23563,1,3,0)
 ;;=3^Osteomyelitis,Chronic Multifocal,Unspec Site
 ;;^UTILITY(U,$J,358.3,23563,1,4,0)
 ;;=4^M86.30
 ;;^UTILITY(U,$J,358.3,23563,2)
 ;;=^5014559
 ;;^UTILITY(U,$J,358.3,23564,0)
 ;;=M86.20^^105^1174^106
 ;;^UTILITY(U,$J,358.3,23564,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23564,1,3,0)
 ;;=3^Osteomyelitis,Subacute,Unspec Site
 ;;^UTILITY(U,$J,358.3,23564,1,4,0)
 ;;=4^M86.20
 ;;^UTILITY(U,$J,358.3,23564,2)
 ;;=^5014535
 ;;^UTILITY(U,$J,358.3,23565,0)
 ;;=M86.8X9^^105^1174^107
 ;;^UTILITY(U,$J,358.3,23565,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23565,1,3,0)
 ;;=3^Osteomyelitis,Unspec Sites
 ;;^UTILITY(U,$J,358.3,23565,1,4,0)
 ;;=4^M86.8X9
 ;;^UTILITY(U,$J,358.3,23565,2)
 ;;=^5014655
 ;;^UTILITY(U,$J,358.3,23566,0)
 ;;=N73.5^^105^1174^110
 ;;^UTILITY(U,$J,358.3,23566,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23566,1,3,0)
 ;;=3^Peritonitis,Female Pelvic,Unspec
 ;;^UTILITY(U,$J,358.3,23566,1,4,0)
 ;;=4^N73.5
 ;;^UTILITY(U,$J,358.3,23566,2)
 ;;=^5015817
 ;;^UTILITY(U,$J,358.3,23567,0)
 ;;=M00.10^^105^1174^111
 ;;^UTILITY(U,$J,358.3,23567,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23567,1,3,0)
 ;;=3^Pneumococcal Arthritis,Unspec Joint
 ;;^UTILITY(U,$J,358.3,23567,1,4,0)
 ;;=4^M00.10
 ;;^UTILITY(U,$J,358.3,23567,2)
 ;;=^5009621
 ;;^UTILITY(U,$J,358.3,23568,0)
 ;;=A92.5^^105^1174^181
